Released Apr 6, 2018, after the close
10-K filed Apr 9, 2018, 99 days after period end · 0001564590-18-007802
Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.84M$1.84M derived+9.0% vs Q4 2016−0.3% vs Q3 2017
Net Income-$1.39M-$1.39M derivedN/M vs Q4 2016N/M vs Q3 2017
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,924,000N/M
Operating Cash Flowderived-$493,000N/M
Free Cash Flowderived-$516,000N/M
Margins · derived
Operating margin-104.5%−35.0 pt vs Q4 2016
Net margin-75.4%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.84M | $1.69M | $1.98M | $1.82M |
| Net Income | -$1.39M | $2.16M | -$1.53M | -$4.60M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
International Stem Cell CORP · CIK 1355790 · Engraved from SEC EDGAR